Pfizer offers the highest forward dividend yield in the healthcare sector, currently standing at 6.86%. The stock also trades at an attractive valuation with a forward P/E ratio of 8.3. Despite facing challenges like the patent cliff, Pfizer has a robust pipeline with strong growth prospects. The company’s dividend track record is impressive, having paid 347 consecutive quarterly dividends and increased dividends for 16 years. Analysts believe Pfizer is not a value trap, with a consensus 12-month price target reflecting an upside potential of over 13%. Overall, Pfizer remains a top pick for investors seeking high dividend yields and deep value.

Read more at Nasdaq.: My Top Dividend-Paying, Deep-Value Stock to Buy in August